Werewolf Therapeutics (HOWL) Competitors $1.08 +0.01 (+0.93%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+0.93%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. CTMX, OGI, GNFT, FDMT, IPHA, VTYX, DERM, PBYI, DMAC, and SPROShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Its Competitors CytomX Therapeutics Organigram Global GENFIT 4D Molecular Therapeutics Innate Pharma Ventyx Biosciences Journey Medical Puma Biotechnology DiaMedica Therapeutics Spero Therapeutics Werewolf Therapeutics (NASDAQ:HOWL) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Do analysts recommend HOWL or CTMX? Werewolf Therapeutics presently has a consensus target price of $8.33, indicating a potential upside of 671.60%. CytomX Therapeutics has a consensus target price of $5.33, indicating a potential upside of 105.13%. Given Werewolf Therapeutics' higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, HOWL or CTMX? CytomX Therapeutics has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.88M25.78-$70.51M-$1.67-0.65CytomX Therapeutics$138.10M1.52$31.87M$0.485.42 Do insiders and institutionals believe in HOWL or CTMX? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer HOWL or CTMX? In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 2 articles in the media. CytomX Therapeutics' average media sentiment score of 0.75 beat Werewolf Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HOWL or CTMX more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Werewolf Therapeutics' net margin of 0.00%. Werewolf Therapeutics' return on equity of -89.37% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf TherapeuticsN/A -89.37% -54.87% CytomX Therapeutics 28.22%-553.71%32.21% Which has more risk & volatility, HOWL or CTMX? Werewolf Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. SummaryCytomX Therapeutics beats Werewolf Therapeutics on 9 of the 13 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.01M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-0.6520.9727.1520.13Price / Sales25.78292.39441.18127.16Price / CashN/A42.7337.5058.41Price / Book0.657.748.085.60Net Income-$70.51M-$54.96M$3.16B$248.43M7 Day Performance-0.09%6.04%3.77%5.15%1 Month Performance-18.80%4.47%3.90%7.62%1 Year Performance-50.91%6.12%34.22%21.56% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.1056 of 5 stars$1.08+0.9%$8.33+671.6%-54.3%$48.01M$1.88M-0.6540News CoverageCTMXCytomX Therapeutics4.2022 of 5 stars$2.27+0.9%$5.33+134.9%+84.4%$181.40M$138.10M4.73170News CoverageOGIOrganigram Global0.9872 of 5 stars$1.35flatN/A-8.3%$180.82M$117.47M13.50860News CoverageGNFTGENFIT2.0798 of 5 stars$3.73+3.2%$13.00+249.0%-12.2%$180.49M$67.00M0.00120News CoveragePositive NewsFDMT4D Molecular Therapeutics2.1296 of 5 stars$3.71-3.4%$29.56+696.6%-80.5%$177.89M$40K-1.17120IPHAInnate Pharma2.5488 of 5 stars$1.82-1.9%$11.00+506.1%-16.1%$170.53M$21.77M0.00220VTYXVentyx Biosciences3.0675 of 5 stars$2.14-8.5%$10.00+367.3%+2.6%$166.52MN/A-1.2230Positive NewsDERMJourney Medical1.8579 of 5 stars$7.18+0.6%$9.50+32.3%+27.3%$166.33M$56.13M-18.4190PBYIPuma Biotechnology4.28 of 5 stars$3.43+3.0%$7.00+104.1%+18.4%$165.27M$230.50M4.45200DMACDiaMedica Therapeutics0.903 of 5 stars$3.90+1.6%$8.00+105.1%+27.1%$164.67MN/A-6.0920SPROSpero Therapeutics3.8908 of 5 stars$2.90-1.4%$5.00+72.4%+124.4%$164.38M$47.98M-2.27150 Related Companies and Tools Related Companies CytomX Therapeutics Alternatives Organigram Global Alternatives GENFIT Alternatives 4D Molecular Therapeutics Alternatives Innate Pharma Alternatives Ventyx Biosciences Alternatives Journey Medical Alternatives Puma Biotechnology Alternatives DiaMedica Therapeutics Alternatives Spero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
